Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BMEA Biomea Fusion
9.840+0.310+3.25%
Close
02/06 16:00 ET
9.8400.0000.00%
Post Mkt Price 02/06 16:51 ET
High
10.000
Open
9.550
Turnover
299.16K
Low
9.257
Pre Close
9.530
Volume
30.65K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Head-To-Head Review: Biomea Fusion (NASDAQ:BMEA) Vs. Amylyx Pharmaceuticals (NASDAQ:AMLX)
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Rating) and Biomea Fusion (NASDAQ:BMEA – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on t
Top Premarket Gainers
07:55 AM EST, 01/26/2023 (MT Newswires) -- Minerva Surgical (UTRS) shares soared 72%, extending Wednesday's rally. MicroAlgo (MLGO) shares surged 27% following a muted session. BuzzFeed (BZFD) shares
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update
Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) was the target of a large growth in short interest in the month of December. As of December 30th, there was short interest totalling 548,400 shares, a
Why Shares of Biomea Fusion Jumped This Week
Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage
Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.
With 34% Ownership in Biomea Fusion, Inc. (NASDAQ:BMEA), Institutional Investors Have a Lot Riding on the Business
If you want to know who really controls Biomea Fusion, Inc. (NASDAQ:BMEA), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the compa
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Precision BioSciences (DTIL)
Biomea Fusion Doses First Patient in COVALENT-102 Trial of BMF-219
Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)A pan
HC Wainwright Comments on Biomea Fusion, Inc.'s FY2027 Earnings (NASDAQ:BMEA)
Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) – Investment analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Biomea Fusion in a note issued to investor
Company Overview
More
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
CEO： Mr. Thomas Andrew Butler
Market： NASDAQ
Listing Date： 04/16/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet